NasdaqGS:ONCBiotechs
A Look At BeOne Medicines (ONC) Valuation After Analyst Upgrades And Positive ASCO 2026 Clinical Updates
BeOne Medicines (NasdaqGS:ONC) is back in focus after a cluster of analyst upgrades to Strong Buy and fresh ASCO 2026 data on three solid tumor candidates, paired with plans for multiple registrational trials.
See our latest analysis for BeOne Medicines.
Despite upbeat ASCO 2026 headlines and analyst upgrades, BeOne’s 1 month share price return is down 13.46% and the year to date share price return is down 13.16%, while the 1 year total shareholder return is 5.57%. This suggests long term...